Original Article AbstractPurpose: This study aims to clinically evaluate the directional dependence of a 2D seven29 ion-chamber array with different intensity-modulated radiotherapy (IMRT) plans. Methods: Twenty-five patients who had already been treated with IMRT plans were selected for the study. Verification plans were created in an Eclipse treatment planning system (TPS) for each treatment plan. The verification plans were executed twice for each patient. The first IMRT plan used a true gantry angle (plan-related approach), and the second plan used a 0° gantry angle (field-related approach). Measurements were performed using a Varian Clinac 2100 iX linear accelerator. The fluence was measured for all the delivered plans and analyzed using Verisoft software. A comparison of the fluence was performed between IMRT with a static gantry (0° gantry angle) and real gantry angles. Results:The results indicate that the Gamma average was 98.8% for IMRT with a 0° gantry angle and 96.616% for IMRT with a true gantry angle. Average percent difference of normalized doses for IMRT delivered with zero degree gantry angle and IMRT with actual gantry angles is 0.15 and 0.88 respectively. Conclusion: The ion chamber of the 2D array used in IMRT verification has angular dependence, reducing the verification accuracy when the 2D array is used for measuring the actual beams of the treatment plan.
The aim of this study was to evaluate the fluence for midline and lateralized tumors for volumetric modulated arc therapy (VMAT) by using a two-dimensional array. Methods: For this study, we selected 60 patients who were undergoing VMAT. The octavius phantom was computed tomography (CT) scanned and imported to the planning system. Verification plans were created for each plan and exported. The measurements were performed using 2D seven29 ion chamber array. Fluence measurement values for all the delivered plans were analyzed using VeriSoft software. The TPS calculated values were then compared with the measured gamma values. Results: The gamma pass percentage for midline tumors was found to be higher than that for lateralized tumors. The standard deviations between the gamma values for midline and lateralized tumors were 1.96 and 2.86, respectively. Moreover, the standard deviations between the point doses for midline and lateralized tumors were 0.360 and 0.283, respectively. The mean gamma passing rate was 96.96% for midline tumors and 96.57% for lateralized tumors for 3%DD/3-mm criteria. There is no significance found in the gamma values for midline and lateralized tumors with p-value 0.08. Conclusion: No particular correlation was found between the gamma pass percentage for midline tumors and that for lateralized tumors. Only a marginal difference was found in the gamma pass percentage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.